By Nana O 
In a significant leap forward for neurorehabilitation, researchers at The University of Texas at Dallas’s Texas Biomedical Device Center (TxBDC) have demonstrated unprecedented rates of recovery for individuals with spinal cord injuries. The pioneering approach, detailed in the prestigious journal Nature on May 21st, combines targeted vagus nerve stimulation with progressive, individualized rehabilitation, yielding meaningful improvements in upper-limb function for patients who had previously seen little to no benefit from therapy alone. This breakthrough positions the UT Dallas scientists on the cusp of a pivotal clinical trial, the final regulatory step before potential Food and Drug Administration (FDA) approval for treating impairments caused by spinal cord injuries.
The therapy, termed closed-loop vagus nerve stimulation (CLV), represents the culmination of over a decade of intensive research in neuroscience and bioengineering at UT Dallas. It leverages a miniature implanted device that delivers precisely timed electrical pulses to the vagus nerve, a crucial communication pathway in the body, synchronized with rehabilitative exercises designed to reactivate damaged neural circuits. While previous research from UT Dallas had shown CLV’s efficacy in rewiring brain areas affected by stroke, its application to spinal cord injury presented a unique challenge, as the underlying neural damage and recovery mechanisms differ significantly.
A Novel Approach for Unmet Needs
Dr. Michael Kilgard, the Margaret Fonde Jonsson Professor of Neuroscience at UT Dallas and the study’s corresponding author, highlighted the critical distinction between stroke and spinal cord injury in the context of CLV therapy. "In stroke, individuals who undergo therapy may naturally see some improvement, and adding CLV can significantly amplify that recovery," Dr. Kilgard explained. "However, this spinal cord injury study is fundamentally different. In our participants, traditional therapy alone yielded no discernible improvements in arm and hand function. This underscores the unique contribution of CLV in cases where conventional rehabilitation has reached its limit."
The study involved 19 participants who had sustained chronic, incomplete cervical spinal cord injuries. These individuals, ranging in age from 21 to 65 and with injuries sustained between one and 45 years prior, underwent a rigorous 12-week rehabilitation program. The program centered on engaging them in simple video games designed to elicit specific upper-limb movements. Crucially, the implanted CLV device was activated only when participants successfully executed these targeted movements, a feedback mechanism that proved instrumental in driving neural plasticity. The results were striking: participants experienced significant gains in arm and hand strength, speed, range of motion, and overall functional capacity.
Enhancing Daily Living Through Restored Function
The implications of these functional improvements extend far beyond the clinic, directly impacting the daily lives of individuals who have lived with debilitating mobility impairments. Dr. Robert Rennaker, Professor of Neuroscience and the Texas Instruments Distinguished Chair in Bioengineering, who was instrumental in designing the miniature implanted CLV device, emphasized this crucial aspect. "These activities allow patients to regain strength, speed, range of motion, and hand function, which directly translates to simplifying their daily living," Dr. Rennaker stated. This sentiment was echoed by Dr. Jane Wigginton, a study co-author, Chief Medical Officer at TxBDC, and co-director of UTD’s Clinical and Translational Research Center, who underscored the profound impact on patients’ lives. "The people in this study have now gained the ability to do things that are meaningful for them and impactful in their lives," she remarked.
Rigorous Study Design and Broad Applicability
The research project served a dual purpose, functioning as both a Phase 1 and Phase 2 clinical trial. This comprehensive design included a randomized placebo-controlled element in its initial phase. Nine of the 19 participants received sham stimulation, mimicking the sensation of active treatment without delivering the therapeutic electrical pulses, for the first 18 therapy sessions. They then transitioned to active CLV treatment for the subsequent 18 sessions. This meticulous methodology allowed researchers to isolate the specific effects of CLV from the placebo effect and the general benefits of rehabilitation.
A particularly encouraging finding from the study was the therapy’s broad applicability. The degree of improvement observed was not influenced by factors that often confound treatment outcomes in spinal cord injury research, such as the age of the participant, the duration since injury, or the severity of residual hand movement. "This approach produces results regardless of these factors, which often cause significant differences in success rates of other types of treatment," Dr. Wigginton noted. This suggests that CLV may offer a viable treatment option for a wider spectrum of individuals with spinal cord injuries than previously thought possible.
A Decade of Innovation Leading to This Moment
The journey to this groundbreaking discovery has been a long and dedicated one, built upon years of foundational research at UT Dallas. TxBDC has been at the forefront of exploring CLV for a diverse range of conditions for over 13 years. This extensive research portfolio has already led to the FDA’s approval of vagus nerve stimulation for treating impaired upper-limb movement in stroke patients, providing a strong precedent for the current spinal cord injury research.
The development of the CLV device itself has also seen remarkable technological advancements. Dr. Rennaker confirmed that the newest generation of the implantable device is approximately 50 times smaller than its predecessor from three years ago. This miniaturization is crucial for patient comfort and practicality, and importantly, the device is designed to be compatible with medical imaging techniques such as MRI, CT scans, and ultrasounds, eliminating a significant barrier to adoption for patients requiring these diagnostic procedures.
The Path Forward: A Pivotal Trial and Future Hopes
With the promising results of this combined Phase 1/2 trial, the UT Dallas team is now poised to advance to a Phase 3 pivotal trial. This next phase will involve a larger cohort of approximately 70 participants across multiple specialized spinal cord injury centers in the United States. The primary objective of this trial will be to confirm the efficacy and safety of CLV on a broader scale, providing the robust data necessary for FDA review.
Dr. Seth Hays, an Associate Professor of Bioengineering and a Fellow of the Eugene McDermott Distinguished Professor in the Erik Jonsson School of Engineering and Computer Science, has been a key member of the CLV project since its earliest stages. He emphasized the historical significance of the current findings. "Prior to this study, no person with spinal cord injury had ever received CLV," Dr. Hays stated. "This is the first evidence that gains can be made. Now we will set about determining how we make this optimally effective."
However, Dr. Hays also tempered expectations with a dose of realism, acknowledging the challenges that lie ahead. "We still have a long road ahead," he cautioned. "For many reasons — financial, regulatory, or scientific — this could still die on the vine. But we have positioned ourselves to succeed." This acknowledgment underscores the rigorous and often uncertain nature of medical research and development.
A Collaborative Effort and Patient Dedication
The success of this research is a testament to the collaborative spirit and dedication of a vast network of individuals. The research team specifically highlighted the invaluable contributions of the dozens of people involved, including the participating patients and key partners at Baylor University Medical Center, Baylor Scott & White Research Institute, and Baylor Scott & White Institute for Rehabilitation.
Dr. Wigginton expressed her deep appreciation for the team’s commitment. "This has been the hardest working, most altruistic group of professionals, and that has been incredibly impactful," she said. Dr. Rennaker further emphasized the profound commitment demonstrated by the patients themselves. "Even outpatient surgery is complex for those with impaired mobility," he noted. "These patients said, ‘Put that device in me’ — that’s a huge commitment. They deserve credit for paving the path for others."
Funding and Future Research
The research initiative was supported by substantial funding, including a grant (N66001-17-2-4011) from the Defense Advanced Research Projects Agency (DARPA), an agency of the Department of Defense, recognizing the potential of this technology to address significant health challenges. Additional support was provided by the Wings for Life Accelerated Translational Program, an organization dedicated to advancing research for spinal cord injury cures.
The scientific team at UT Dallas, including other affiliated co-authors such as Joseph Epperson (TxBDC research associate), Emmanuel Adehunoluwa (cognition and neuroscience doctoral student), Amy Porter (TxBDC director of operations), Holle Carey Gallaway (TxBDC research biomedical engineer), and David Pruitt (researcher), are continuing their work to refine and optimize CLV therapy. Dr. Kilgard holds a financial interest in MicroTransponder Inc., a company that markets vagus nerve stimulation therapy for stroke, while Dr. Rennaker is the founder and CEO of XNerve, the company that developed the device utilized in this study. These disclosures are part of the standard scientific process, ensuring transparency in research and development.
The implications of this research are far-reaching, offering a beacon of hope for millions of individuals worldwide living with the devastating effects of spinal cord injury. The prospect of restoring lost function and improving quality of life through an innovative bioelectronic therapy marks a pivotal moment in the ongoing quest for effective neurological treatments.